Bavarian Nordic, located in DTU Science Park, is partnering with the biopharmaceutical company Dynavax in connection with the launch of a new hepatitis b vaccine in Germany.
That is what the company said in a statement Thursday, May 27th, 2021.
Heplisav b, the vaccine against viral diseases to the liver, is going to be marketed and distributed by Bavarian for Dynavax. It is expected to be launched in the fourth quarter of 2021.
In February, the European Commission authorized the marketing of Heplisav b in the EU. There is no cure for hepatitis b, and this vaccine is the only FDA- and EU-approved hepatitis b vaccine that can be used to fully vaccinate people within a month.
Bavarian CEO Paul Chaplin looks forward to assisting Dynavax later this year. He explains how Bavarian is looking forward to expand its commercial operations in the largest EU market via marketing and distribution of a product that complements its business.
Bavarian make their own vaccines against rabies and tick-borne encephalitis.